vs
AMREP CORP.（AXR）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是AMREP CORP.的1.3倍（$19.6M vs $14.6M），AMREP CORP.净利率更高（21.6% vs -177.4%，领先199.0%），AMREP CORP.同比增速更快（93.8% vs -11.5%），AMREP CORP.自由现金流更多（$5.4M vs $-23.1M），过去两年STANDARD BIOTOOLS INC.的营收复合增速更高（-12.2% vs -13.6%）
AMREP是一家总部位于美国新泽西州普林斯顿的企业，核心业务涵盖房地产与媒体服务领域。公司前身为美国地产石油公司，于1961年正式成立，在相关行业拥有六十余年的发展运营历史。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
AXR vs LAB — 直观对比
营收规模更大
LAB
是对方的1.3倍
$14.6M
营收增速更快
AXR
高出105.3%
-11.5%
净利率更高
AXR
高出199.0%
-177.4%
自由现金流更多
AXR
多$28.5M
$-23.1M
两年增速更快
LAB
近两年复合增速
-13.6%
损益表 — Q3 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $14.6M | $19.6M |
| 净利润 | $3.1M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | 20.6% | -168.5% |
| 净利率 | 21.6% | -177.4% |
| 营收同比 | 93.8% | -11.5% |
| 净利润同比 | 338.9% | -28.8% |
| 每股收益（稀释后） | $0.58 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXRLAB
| Q1 26 | $14.6M | — | ||
| Q4 25 | $9.4M | — | ||
| Q3 25 | $17.9M | $19.6M | ||
| Q2 25 | $11.2M | $21.8M | ||
| Q1 25 | $7.5M | $40.8M | ||
| Q4 24 | $11.9M | — | ||
| Q3 24 | $19.1M | $22.1M | ||
| Q2 24 | $19.5M | $22.5M |
净利润AXRLAB
| Q1 26 | $3.1M | — | ||
| Q4 25 | $1.2M | — | ||
| Q3 25 | $4.7M | $-34.7M | ||
| Q2 25 | $3.9M | $-33.5M | ||
| Q1 25 | $717.0K | $-26.0M | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | $4.1M | $-26.9M | ||
| Q2 24 | $4.1M | $-45.7M |
毛利率AXRLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% |
营业利润率AXRLAB
| Q1 26 | 20.6% | — | ||
| Q4 25 | 11.9% | — | ||
| Q3 25 | 34.4% | -168.5% | ||
| Q2 25 | 31.7% | -118.1% | ||
| Q1 25 | 5.7% | -80.8% | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 26.1% | -120.9% | ||
| Q2 24 | 23.9% | -134.5% |
净利率AXRLAB
| Q1 26 | 21.6% | — | ||
| Q4 25 | 12.8% | — | ||
| Q3 25 | 26.3% | -177.4% | ||
| Q2 25 | 34.8% | -153.7% | ||
| Q1 25 | 9.5% | -63.8% | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 21.3% | -122.0% | ||
| Q2 24 | 21.2% | -203.3% |
每股收益（稀释后）AXRLAB
| Q1 26 | $0.58 | — | ||
| Q4 25 | $0.22 | — | ||
| Q3 25 | $0.87 | $-0.09 | ||
| Q2 25 | $0.73 | $-0.09 | ||
| Q1 25 | $0.13 | $-0.07 | ||
| Q4 24 | $0.75 | — | ||
| Q3 24 | $0.76 | $-0.07 | ||
| Q2 24 | $0.77 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $50.0M | $129.4M |
| 总债务越低越好 | $21.0K | — |
| 股东权益账面价值 | $139.4M | $399.7M |
| 总资产 | $143.9M | $539.6M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资AXRLAB
| Q1 26 | $50.0M | — | ||
| Q4 25 | $44.6M | — | ||
| Q3 25 | $48.9M | $129.4M | ||
| Q2 25 | $39.5M | $158.6M | ||
| Q1 25 | $36.9M | $150.9M | ||
| Q4 24 | $40.1M | — | ||
| Q3 24 | $40.4M | $210.6M | ||
| Q2 24 | $29.7M | $269.8M |
总债务AXRLAB
| Q1 26 | $21.0K | — | ||
| Q4 25 | $23.0K | — | ||
| Q3 25 | $25.0K | — | ||
| Q2 25 | $26.0K | — | ||
| Q1 25 | $29.0K | — | ||
| Q4 24 | $32.0K | — | ||
| Q3 24 | $34.0K | $55.2M | ||
| Q2 24 | $35.0K | $55.1M |
股东权益AXRLAB
| Q1 26 | $139.4M | — | ||
| Q4 25 | $136.0M | — | ||
| Q3 25 | $134.7M | $399.7M | ||
| Q2 25 | $130.0M | $424.5M | ||
| Q1 25 | $126.0M | $454.6M | ||
| Q4 24 | $125.1M | — | ||
| Q3 24 | $122.2M | $489.3M | ||
| Q2 24 | $118.0M | $510.3M |
总资产AXRLAB
| Q1 26 | $143.9M | — | ||
| Q4 25 | $140.1M | — | ||
| Q3 25 | $140.7M | $539.6M | ||
| Q2 25 | $133.8M | $557.0M | ||
| Q1 25 | $128.9M | $579.6M | ||
| Q4 24 | $129.1M | — | ||
| Q3 24 | $127.0M | $681.5M | ||
| Q2 24 | $122.8M | $708.7M |
负债/权益比AXRLAB
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | 0.11× | ||
| Q2 24 | 0.00× | 0.11× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.4M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $5.4M | $-23.1M |
| 自由现金流率自由现金流/营收 | 37.0% | -118.1% |
| 资本支出强度资本支出/营收 | 0.1% | 4.5% |
| 现金转化率经营现金流/净利润 | 1.72× | — |
| 过去12个月自由现金流最近4个季度 | $20.2M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流AXRLAB
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $9.5M | $-22.2M | ||
| Q2 25 | $10.2M | $-20.7M | ||
| Q1 25 | $-3.2M | $-30.3M | ||
| Q4 24 | $-182.0K | — | ||
| Q3 24 | $10.7M | $-27.9M | ||
| Q2 24 | $10.7M | $-39.0M |
自由现金流AXRLAB
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $9.5M | $-23.1M | ||
| Q2 25 | $9.7M | $-22.6M | ||
| Q1 25 | $-3.3M | $-35.3M | ||
| Q4 24 | $-268.0K | — | ||
| Q3 24 | $10.7M | $-30.1M | ||
| Q2 24 | $10.3M | $-41.0M |
自由现金流率AXRLAB
| Q1 26 | 37.0% | — | ||
| Q4 25 | -45.9% | — | ||
| Q3 25 | 53.2% | -118.1% | ||
| Q2 25 | 86.4% | -103.6% | ||
| Q1 25 | -43.4% | -86.6% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | 55.8% | -136.4% | ||
| Q2 24 | 52.5% | -182.2% |
资本支出强度AXRLAB
| Q1 26 | 0.1% | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.1% | 4.5% | ||
| Q2 25 | 5.2% | 8.7% | ||
| Q1 25 | 0.3% | 12.4% | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.2% | 10.2% | ||
| Q2 24 | 2.3% | 8.6% |
现金转化率AXRLAB
| Q1 26 | 1.72× | — | ||
| Q4 25 | -3.54× | — | ||
| Q3 25 | 2.03× | — | ||
| Q2 25 | 2.63× | — | ||
| Q1 25 | -4.51× | — | ||
| Q4 24 | -0.05× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 2.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXR
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
